Showing 1061-1070 of 5404 results for "".
- Short-Term Corticosteroid Use Not Linked to Increased IOP in 3 Trialshttps://practicaldermatology.com/news/short-term-corticosteroid-use-not-linked-to-increased-iop-in-3-trials/2487073/A pooled analysis of 3 randomized clinical trials found no evidence that short-term topical or systemic corticosteroid therapy increases intraocular pressure (IOP), a concern associated with corticosteroid-induced glaucoma. T
- Iron Oxides in Tinted Sunscreens May Improve Hyperpigmentation Protection: Studyhttps://practicaldermatology.com/news/iron-oxides-in-tinted-sunscreens-may-improve-hyperpigmentation-protection-study/2487035/A literature review and product analysis published in the Journal of Drugs in Dermatology highlighted growing evidence supporting the use of iron oxides in tinted sunscreens for managing hyperpigmentation, while also identif
- Topical NAC Plus Doxycycline Shows Benefit in Moderate Acnehttps://practicaldermatology.com/news/topical-nac-plus-doxycycline-shows-benefit-in-moderate-acne/2486948/Topical N-acetylcysteine (NAC) plus doxycycline was associated with greater improvement than benzoyl peroxide (BPO) plus doxycycline in patients
- Rapid Weight Loss Brings Expanding Soft Tissue Concerns to Dermatologyhttps://practicaldermatology.com/news/rapid-weight-loss-brings-expanding-soft-tissue-concerns-to-dermatology/2486936/A new analysis suggests rapid weight loss from GLP-1 agents, bariatric surgery, or lifestyle change is associated with measurable declines in skin elasticity and soft tissue volume.Rapid and intentional weight loss (driven by bariatric surgery, glucagon-l
- Analysis: PRS Improves Melanoma Risk Predictionhttps://practicaldermatology.com/news/tildrakizumab-matches-risankizumab-guselkumab-in-mid-term-psoriasis-outcomes/2486903/A polygenic risk score (PRS) improved prediction of invasive cutaneous melanoma when added to an established clinical risk model, according to findings from a recent genome-wide association analysis. The PRS was derived from a
- Dr. Miriam Bettencourt Speaks on Measles Resurgence and the Dermatologist’s Rolehttps://practicaldermatology.com/news/dr-miriam-bettencourt-speaks-on-measles-resurgence-and-the-dermatologists-role/2486877/As the ominous music from the “Mission Impossible” movies played over the speakers, a dramatic voice spoke: “Good morning, doctors. Sixty years of safe and effective vaccine has resulted in the eradication of measles. Recently, however, a distrust of science has pr
- AQUA Announces Partnership with Steele Dermatologyhttps://practicaldermatology.com/news/aqua-announces-partnership-with-steele-dermatology/2486768/AQUA Dermatology has announced a new partnership with Steele Dermatology, expanding its presence in the Atlanta metropolitan area, according to a press release.AQUA, backed by private equity firms Gryphon Investors and GTCR, continues to scale its network
- SEEN Launches Dermatologist-Designed Clarifying Shampoo as Scalp Care Trend Surgeshttps://practicaldermatology.com/news/seen-launches-dermatologist-designed-clarifying-shampoo-as-scalp-care-trend-surges/2486594/As scalp care continues to gain momentum within the broader beauty and wellness industry, dermatologist-founded brand SEEN is expanding its portfolio with the launch of its new Scalp Clarifying Shampoo, a product designed to bridge the gap between hair care and skin
- Rademikibart Shows High Long-Term Efficacy in Atopic Dermatitishttps://practicaldermatology.com/news/rademikibart-shows-high-long-term-efficacy-in-atopic-dermatitis/2486495/Rademikibart, a next-generation anti–IL-4 receptor alpha monoclonal antibody, demonstrated robust and sustained efficacy in moderate-to-severe atopic dermatitis (AD) through 52 weeks, according to Phase 3 RADIANT-AD data presented by Cheng Zhou, MD, at the American Academy of Dermatology (AAD) 20
- Nemolizumab Shows Efficacy in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/nemolizumab-shows-efficacy-in-pediatric-atopic-dermatitis/2486457/Nemolizumab, an IL-31 receptor alpha (IL-31Rα) antagonist, demonstrated favorable pharmacokinetics, sustained efficacy, and a consistent safety profile in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to Phase 2 data presented by Linda Stein Gold, MD, at th